Dolomite and GigaGen Collaborate to Develop Novel Droplet Merging Technology
News Feb 17, 2012
Dolomite has announced its collaboration with GigaGen Inc. (San Francisco, CA) in the development of a novel Droplet Merger Chip for massively parallel single cell genetic analysis.
Measuring just 15mm x 22.5mm, the novel glass microfluidic chip facilitates fast and consistent merging of two individual droplet streams, benefiting a wide range of applications including DNA amplification, biochemical analysis, single cell analysis and high throughput experimentation.
Unlike other methods which incorporate expensive and bulky high voltage electronics to merge droplets using electrostatic forces, the Droplet Merger Chip works by simply “squeezing” droplets together in a carefully designed merging chamber.
The result is a unique microfluidic device, which points the way to low cost disposable chips in future versions.
“A simple and reliable droplet merging technology is an important step forward for us”, said Dr. David Johnson, CEO and founder of GigaGen Inc., adding “We are now using these chips in our game-changing system for massively parallel single cell genetic analysis.”
GigaGen Inc. filed a patent application describing the chip design and its applications in the field of genetic analysis of cells.
As part of a license agreement with GigaGen Inc., Dolomite will be offering the technology later this year to research users in academia and commercial users in a wide range of application areas.
“Many of our customers have asked us for chips to create droplets, merge them, and then carry out further processing and analysis”, commented Dr. Andrew Lovatt, CEO of Dolomite.
Dr. Lovatt continued, “Our partnership with Sphere Fluidics gives us additional capability in selecting the surfactants we use, to optimize droplet behaviour and stability under a wide range of temperature and biological conditions.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018